FDA Clinical Hold Halts Aardvark’s ARD-101 Late-Stage Program

Aardvark Therapeutics, Inc. ( (AARD) ) has shared an announcement.

On May 14, 2026, Aardvark Therapeutics said the U.S. Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101, following the company’s earlier voluntary pause. The hold affects all ongoing studies, including the Phase 3 HERO trial in Prader-Willi Syndrome patients and an open-label extension, temporarily halting late-stage development of the company’s flagship therapy.

In response, Aardvark plans to unblind accumulated data from both Phase 3 studies to evaluate overall efficacy and safety and to guide decisions on the ARD-101 program’s future. The company reported dosing 68 patients in the randomized HERO trial and 19 in the extension as of late February 2026 and held $91.2 million in cash and investments as of March 31, 2026, which it expects to fund operations into mid-2027.

The most recent analyst rating on (AARD) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Aardvark Therapeutics, Inc. stock, see the AARD Stock Forecast page.

Spark’s Take on AARD Stock

According to Spark, TipRanks’ AI Analyst, AARD is a Neutral.

The score is weighed down primarily by weak financial performance (pre-revenue, widening losses, and substantial cash burn). Corporate events add near-term clinical risk due to the Phase 3 enrollment pause, partially offset by financing flexibility and protocol expansion. Technicals are neutral-to-mixed and valuation support is limited given negative earnings and no dividend.

To see Spark’s full report on AARD stock, click here.

More about Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics that activate innate homeostatic pathways to suppress hunger. Its lead programs target Prader-Willi Syndrome and other metabolic diseases, with a focus on hunger-associated indications and potential complementary use with anti-appetite therapies.

The company’s lead candidate, ARD-101, is an oral small molecule designed to stimulate gut-peptide hormone release via bitter taste receptor activation. ARD-101 has been studied in Phase 3 trials for treating hyperphagia in patients with Prader-Willi Syndrome, a rare genetic disorder marked by insatiable hunger.

Average Trading Volume: 283,948

Technical Sentiment Signal: Sell

Current Market Cap: $133.3M

For detailed information about AARD stock, go to TipRanks’ Stock Analysis page.